Author:
Kasper Bernd,Benson Charlotte
Publisher
Springer International Publishing
Reference57 articles.
1. Agulnik M, Yarber JL, Okuno SH et al (2013) An open-label multicentre, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid haemangioendotheliomas. Ann Oncol 24(1):257–263
2. Antonescu CR, Yoshida A, Guo T et al (2009) KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 69(18):7175–7179
3. Attia S, Okuno SH, Robinson SI et al (2015) Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma. Rare Tumours 7(2):5992
4. Azizi AA, Haberler C, Czech T et al (2006) Vascular- endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 7(6):521–523
5. Belotti D, Vergani V, Drudis T et al (1996) The microtubule–affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843–1849